What should you know about extensive lobular carcinoma in situ?

Lobular carcinoma in situ, or LCIS, is also called lobular neoplasia. It describes abnormal cells in the lobules, the milk-producing parts of the breast. Classic LCIS is generally treated as a marker of increased future breast cancer risk rather than an invasive cancer itself. The word extensive may refer to how much tissue contains LCIS or to findings seen across several samples. Its meaning depends on the pathology pattern, imaging appearance and whether another abnormality is present.

A breast specialist may compare the biopsy with mammography or other imaging and decide whether more tissue sampling is appropriate. Many people are offered a personalised surveillance plan, with clinical reviews and breast imaging at intervals chosen for their risk profile. Risk-reducing endocrine therapy can be discussed; it may lower the chance of some hormone-sensitive breast cancers but can cause side effects. Surgery is not automatically required for every LCIS finding, and the decision should reflect the pathology, family history, imaging and your preferences.

Contact your breast clinic if you notice a new lump, skin or nipple change, bloody discharge, or persistent focal breast discomfort. These symptoms can have many explanations, but they deserve examination. After a biopsy, seek prompt advice for worsening redness, swelling, fever or fluid from the wound.

Ask whether the report describes classic or pleomorphic LCIS, whether the imaging and pathology agree, and what surveillance schedule fits your risk. Also ask about the benefits and side effects of risk-reducing endocrine therapy.